ALLIANCEBERNSTEIN L.P. - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 39 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$702,331
-30.2%
58,140
-6.1%
0.00%
Q1 2024$1,006,819
+135.3%
61,920
-1.3%
0.00%
Q4 2023$427,819
+1.6%
62,730
-18.8%
0.00%
Q3 2023$421,225
-62.9%
77,289
-53.7%
0.00%
Q2 2023$1,133,855
+45.4%
166,989
+7.3%
0.00%
Q1 2023$779,751
+2.7%
155,6390.0%0.00%
Q4 2022$759,518
-97.6%
155,639
-92.8%
0.00%
-100.0%
Q3 2022$31,004,000
-27.2%
2,150,064
-23.6%
0.02%
-21.1%
Q2 2022$42,604,000
+20.8%
2,815,865
-5.2%
0.02%
+35.7%
Q1 2022$35,274,000
+12.0%
2,969,159
+52.9%
0.01%
+27.3%
Q4 2021$31,485,000
-22.2%
1,942,334
+37.0%
0.01%
-31.2%
Q3 2021$40,464,000
-11.2%
1,417,809
+5.1%
0.02%
-11.1%
Q2 2021$45,583,000
+22.4%
1,348,596
+9.5%
0.02%
+12.5%
Q1 2021$37,236,000
-25.6%
1,231,338
+21.9%
0.02%
-33.3%
Q4 2020$50,021,000
+35.8%
1,010,319
+5.3%
0.02%
+20.0%
Q3 2020$36,836,000
-3.9%
959,516
+8.1%
0.02%
-13.0%
Q2 2020$38,336,000
+56.6%
887,397
-5.4%
0.02%
+27.8%
Q1 2020$24,475,000
-7.3%
937,729
+11.0%
0.02%
+20.0%
Q4 2019$26,390,000
+32.3%
844,464
+10.3%
0.02%
+25.0%
Q3 2019$19,954,000
+17.2%
765,701
+2.9%
0.01%
+9.1%
Q2 2019$17,019,000
-2.2%
744,155
+12.1%
0.01%0.0%
Q1 2019$17,404,000
+53.8%
664,006
+19.4%
0.01%
+37.5%
Q4 2018$11,316,000
+31.1%
556,338
+71.2%
0.01%
+33.3%
Q3 2018$8,632,000324,9900.01%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
Paradigm Biocapital Advisors LP 3,870,594$46,756,7761.79%
Caligan Partners LP 582,078$7,031,5021.64%
Sofinnova Investments, Inc. 2,194,278$26,506,8781.38%
Cormorant Asset Management, LP 1,450,000$17,516,0001.01%
Soleus Capital Management, L.P. 647,982$7,827,6230.69%
Virtus ETF Advisers LLC 27,332$330,1710.16%
Polar Capital Holdings Plc 1,831,000$22,118,4800.13%
EntryPoint Capital, LLC 6,152$74,3160.11%
BOOTHBAY FUND MANAGEMENT, LLC 369,360$4,461,8690.11%
RICE HALL JAMES & ASSOCIATES, LLC 89,735$1,083,9990.06%
View complete list of Y-MABS THERAPEUTICS INC shareholders